Table 1.

Summary of patient characteristics (FAS)

	Oral palonosetron						IV palonosetron
	0.25 mg (N = 155)		0.50 mg (N = 160)		0.75 mg (N = 158)		0.25 mg (N = 162)
	Mean	SD	Mean	SD	Mean	SD	Mean	SD
Age (years)	57.1	11.9	56.1	12.3	55.8	12.7	57.7	12.7
	n	%	n	%	n	%	n	%
Gender
Male	40	25.8	42	26.3	44	27.8	45	27.8
Female	115	74.2	118	73.8	114	72.2	117	72.2
Ethnic group
White	111	70.7	112	69.6	106	67.1	115	70.6
Black	2	1.3	1	0.6	2	1.3	0	0.0
Hispanic	43	27.4	45	28.0	49	31.0	45	27.6
Asian	1	.0.6	1	0.6	0	0.0	2	1.2
Other	0	0.0	2	1.2	1	0.6	1	0.6
Main cancer type
Breast cancer	81	52.3	82	51.3	82	51.9	85	52.5
Colon cancer	11	7.1	8	5.0	12	7.6	7	4.3
Lung malignant neoplasm	8	5.2	8	5.0	4	2.5	12	7.4
Chemotherapy history
Naïve	95	61.3	91	56.9	93	58.9	96	59.3
Non-naïve	60	38.7	69	43.1	65	41.1	66	40.7
Alcohol consumption
No	101	65.2	86	53.8	88	55.7	94	58.0
Rarely	30	19.4	41	25.6	43	27.2	34	21.0
Occasionally	21	13.5	27	16.9	25	15.8	31	19.1
Regularly	3	1.9	6	3.8	2	1.3	3	1.9

N number of patients in a specific group, n number of patients in the relevant category, % percentage based on N, SD standard deviation